Seattle Genetics Inc (SGEN)

SGEN (NASDAQ:Drugs)
$35.25
pos +0.60
+1.73%
Today's Range: 34.63 - 36.07 | SGEN Avg Daily Volume: 985,100
Last Update: 10/20/14 - 4:00 PM EDT
Volume: 934,999
YTD Performance: -13.14%
Open: $34.65
Previous Close: $34.65
52 Week Range: $30.80 - $55.99
Oustanding Shares: 123,447,871
Market Cap: 4,287,344,560
6-Month Chart
TheStreet Ratings Grade for SGEN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 2 3 3 2
Moderate Sell 1 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.67 2.56 2.56 2.50
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -57.88
Price Earnings Comparisons:
SGEN Sector Avg. S&P 500
-57.88 0.00 26.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.67% -17.26% 70.44%
GROWTH 12 Mo 3 Yr CAGR
Revenue 27.70 1.51 0.35
Net Income 0.00 -0.06 0.00
EPS 0.00 -0.23 0.00
Earnings for SGEN:
EBITDA -0.05B
Revenue 0.27B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.25 $-0.29 $-0.82 $-0.64
Number of Analysts 8 7 9 9
High Estimate $-0.15 $-0.26 $-0.70 $-0.26
Low Estimate $-0.30 $-0.37 $-0.94 $-1.05
Prior Year $-0.19 $-0.13 $-0.51 $-0.82
Growth Rate (Year over Year) -33.55% -123.08% -61.66% 21.83%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Bearish
Sep 30, 2014 | 7:42 AM EDT
SGEN was downgraded form Neutral to Underperform, Bank of America/Merrill Lynch said. $34 price target. Aethera data was not as positiv...
A HERO may still emerge.
Become more aggressive about the real valuations of companies.
The $193 level on the SPY will be key today.
Thursday's SPY trade plan will involve fading the edges,
You're looking at one.
Bullish
May 06, 2014 | 7:19 AM EDT
SGEN was upgraded to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $40 price target. 
For these kinds of growth stocks, you have no choice but to wait.
Here are some specific stocks working as parables right now.

Columnist Conversations

FB has earnings due out on 10-28-2014, after the market closes. I will write a full earnings preview for Mark...
Solid opening day to trading week for a change as indices across the board as even the DJIA manages to end up ...
Apple reports after the close today. St expecting Q4 rev of $39.877 billion, up 6.4%. EPS of $1.31. FY14 rev o...
The squeezing high we has been looking for, turned out to surpass our wildest expectations. Nonetheless, we be...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.